Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules Authors: Davide Serrano, Harriet Johansson, Bjørn-Erik Bertelsen, Sara Gandini, Gunnar Mellgren, Parijatham Thomas, Katherine D Crew, Nagi B Kumar, Debora Macis, Valentina Aristarco, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Mauro D’Amico, Tania Buttiron-Webber, Irene Maria Briata, Stefano Spinaci, Viviana Galimberti, Lana A Vornik, Eduardo Vilar, Powel H Brown, Brandy M Heckman-Stoddard, Eva Szabo, Bernardo Bonanni, Andrea DeCensi Published: 2024 ABSTRACT AbstractThe drug’s activity at the target tissue could help to define the minimal effective dose to promote cancer preventive therapy. Here we present exemestane and sex hormone concentrations within breast tissue from a presurgical study of alternative exemestane schedules. Postmenopausal women candidates for breast surgery for estrogen receptor-positive breast cancer were randomly assigned to exemestane 25 mg once daily (QD), 25 mg 3 times/week (TIW), or 25 mg per week (QW) for 4-6 weeks before surgery. Drug and sex hormones were analyzed from homogenized frozen tissue using a QTRAP 6500+ LC-MS/MS System. Tissue drug concentrations were detectable only in the QD arm with higher concentrations in nonmalignant tissue. Estradiol was nearly suppressed in all groups in the nonmalignant tissue (QD vs TIW P = .364 and QD vs QW P = .693). In contrast, a dose-response trend was observed in cancer tissue. Based on estradiol suppression in nonmalignant tissue, lower exemestane schedules should be explored for breast cancer preventive therapy. Trial Registration: Clinical Trials.gov NCT02598557 and EudraCT 2015-005063-1 Breast cancer preventive therapy has succeeded in several phase III clinical trials, using estrogen receptor modulators as well as aromatase inhibitors (1-3). However, its uptake in clinical practice is low, mainly for fear of serious adverse events or high discontinuation rate for worsening of quality of life (4,5). To overcome this barrier, our group has extensively studied low doses of tamoxifen, and a phase III study proved that 5 mg per day of tamoxifen can substantially reduce recurrence from ductal or lobular carcinoma in situ or atypical ductal hyperplasia with negligible side effects and a carryover efficacy of up to 10 years of follow-up (6). Along this line, we have recently completed a presurgical study using alternative exemestane schedules showing a noninferior estradiol suppression of exemestane 3 times/week vs the standard daily dose in compliant participants (7). Microenvironment stimulations have great importance in breast carcinogenesis, and estrogen levels in the mammary gland are higher compared with the plasma (8). Moreover, breast tissue estrogen concentrations are similar in postmenopausal and premenopausal women (9), with inter-individual variability related to the expression of the estrogen receptor (ER), which is higher in ER-positive cancer (10). Here, we analyzed the concentrations of exemestane, its main metabolite 17-OH-exemestane, and sex hormones in the malignant and nonmalignant breast tissue within the above-mentioned presurgical study to further define the minimal effective dose of exemestane for therapeutic prevention. The study design was described in detail in a recent publication (11). Briefly, this was a presurgical, 3-arm, double-blind, phase IIb trial. The main inclusion criteria were postmenopausal patients with confirmed ER-positive breast cancer candidates for surgery. Women were randomly assigned (1:1:1) to either exemestane, 25 mg, once daily, 3 times per week, or once a week for 4 to 6 weeks, time lag chosen to be able to maintain the weekly dose schedule and some flexibility for the surgeon schedule. The protocol was approved by the National Cancer Institute (NCI) Central Institutional Review Board (IRB) and the local Italian IRBs (registered at Clinical Trials.gov NCT02598557 and IEO 370 EudraCT 2015-005063-16); and the Regional Committee for Medical and Health Research Ethics in Western Norway (40213). All participants signed written informed consent. All 5 centers were encouraged to include minority races and ethnicities in the study, but the study was not powered to assess the impact of racial or ethnic or ancestry-based differences. Snap-frozen specimens from the tumor and nonmalignant tissue were collected at surgery. The analytes were detected on Mass Spectrometer by electrospray ionization. Samples were homogenized using zirconium beads and a Tissue Lyser II, and the organic phase was transferred to glass vials and evaporated. The extracts were reconstituted in a methanol solution before analysis. The samples were analyzed using a QTRAP 6500+ LC-MS/MS System (SCIEX); positive electrospray ionization (ESI) mode was used for exemestane and 17-OH-exemestane, and negative ESI mode for sex hormones. Values of 15.5 fmol/g for estradiol, 4.5 fmol/g for estrone, 43.5 fmol/g for exemestane; 65 fmol/g for 17-OH-exemestane; and 47 fmol/g for testosterone were below the lower detection limit (12). Serum exemestane and 17-OH-exemestane and tissue biomarkers, as median values and interquartile ranges (IQR) post-treatment, are presented by arms and type of tissue (malignant and nonmalignant). Median values and IQR of Ki-67%, PgR %, and ER % expression are presented at baseline and as the change in time by arm. Contrasts by arms were evaluated through ANCOVA models adjusted for Body Mass Index (BMI) and age. The normal distribution of residuals from the full model was graphically checked. All P values were 2-sided with 5% significance level. Out of 180 participants (155 were White non-Hispanic), we collected 94 cancer samples and 117 nonmalignant samples to analyze exemestane, 17-OH-exemestane, and sex steroids (CONSORT statement is depicted in Supplementary Figure 1, available online). All participants in this subgroup were treatment-compliant, and their age and BMI were well-balanced (data not shown). Exemestane and 17-OH-exemestane tissue concentrations were detectable only in the once daily arm, whereas the other two arms were below the lower detection limit. Median exemestane and 17-OH-exemestane levels accumulated 4- to 5-fold in nonmalignant tissue compared with malignant tissue in the once daily arm (3807 fmol/g vs 17485 fmol/g for exemestane and 338 fmol/g vs 1343 fmol/g for 17-OH-exemestane, respectively; see Table 1). Table 1.Median interquartile range of exemestane 17-OH-exemestane and sex hormones Exe 25 QDExe 25 TIWExe 25 QW P a QD vs TIW P a QD vs QWSerum(n = 55)(n = 56)(n = 60)Exemestane (pmol/L)3216.5 (2320; 4567)513 (341; 727)24.3 (16.6; 45.5)<.0001<.000117-OH-exemestane (pmol/L)1069 (644; 1657)196 (119; 363)7 (7; 22.3)<.0001<.0001Malignant tissue(n = 32)(n = 31)(n = 31)Exemestane (fmol/g)3807 (1663; 7194)< LDL (